What is IPH6401/SAR445514?
IPH6401/SAR445514 (SAR’514) is a trifunctional anti-BCMA NKp46/CD16 NK cell engager using Sanofi’s proprietary CROSSODILE® multi-functional platform, which comprises the Cross-Over-Dual-Variable-Domain (CODV) format.
Mechanism of action
It induces a dual targeting of the NK activating receptors, NKp46 and CD16, for an optimized NK cell activation, based on Innate’s ANKET® (Antibody-based NK cell Engager Therapeutics) proprietary platform.
SAR445514/IPH6401 is now developped in autoimmune indications.
The Company has a research collaboration and licensing agreement with Sanofi to apply Innate’s proprietary platform to the development of innovative multi-specific antibody formats engaging NK cells through the activating receptors NKp46 and CD16 to kill tumor cells now called the ANKET platform.
Under the terms of the license agreement, Sanofi will be responsible for the development, manufacturing and commercialization of products resulting from the research collaboration. Innate Pharma will be eligible to up to €400m in development and commercial milestone payments as well as royalties on net sales. A new licensing agreement was signed with Sanofi in 2022, to include new drug candidates in the collaboration, bringing the total value of the agreement to 1.75 billion euros.
In April 2025, the Company announced review of their January 2016 Research Collaboration and License Agreement. In alignment with its current strategic priorities, Sanofi will opt to pursue the development of SAR’514/IPH6401 (BCMA ANKET®) in autoimmune indications under the terms of the 2016 License Agreement.
Publications, posters and presentations